JOHN VIERLING to Deoxycytidine
This is a "connection" page, showing publications JOHN VIERLING has written about Deoxycytidine.
Connection Strength
0.196
-
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):524-37.
Score: 0.098
-
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23.
Score: 0.098